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Summary {#efs25710-sec-0001}
=======

In accordance with Article 6 of Regulation (EC) No 396/2005, Syngenta submitted an application to the competent national authority in France (evaluating Member State, EMS) to modify the existing maximum residue level (MRL) for the active substance emamectin benzoate in peaches. The EMS‐FR drafted an evaluation report in accordance with Article 8 of Regulation (EC) No 396/2005, which was submitted to the European Commission and forwarded to the European Food Safety Authority (EFSA) on 5 March 2015. To accommodate for the intended use of emamectin benzoate, the EMS‐FR proposed to raise the existing MRL from 0.03 mg/kg to 0.09 mg/kg. A second request was submitted by Syngenta to the competent national authority in Italy to modify the MRL emamectin benzoate in kiwi. The EMS‐IT drafted an evaluation report in accordance with Article 8 of Regulation (EC) No 396/2005, which was submitted to the European Commission and forwarded to EFSA on 9 November 2015. To accommodate for the intended use of emamectin benzoate, the EMS‐IT proposed to raise the existing MRL of emamectin benzoate in kiwi from the limit of quantification (LOQ) of 0.01 mg/kg to 0.15 mg/kg.

EFSA assessed the applications and the evaluation reports as required by Article 10 of the MRL regulation. EFSA identified data gaps, which were requested from both the EMSs France and Italy. On 11 December 2018 and 1 March 2019, France and Italy respectively, submitted the requested information in the form of an evaluation report, which replaced the previously submitted versions.

Based on the conclusions derived by EFSA in the framework of Directive 91/414/EEC, the data evaluated under previous MRL assessments and the additional data provided by the EMS in the framework of this application, the following conclusions are derived.

The metabolism of emamectin benzoate following foliar application was investigated in crops belonging to the groups of fruit crops, leafy crops and cereals.

Studies investigating the effect of processing on the nature of emamectin benzoate (hydrolysis studies) demonstrated that the active substance significantly degrades under standard hydrolysis condition (ca. 20%) to MSB1a, AB1a and several unknown compounds.

As the proposed uses of emamectin benzoate are on permanent crops, investigations of residues in rotational crops are not required.

Based on the metabolic pattern identified in metabolism studies, hydrolysis studies, the toxicological significance of metabolites and degradation products, the residue definition for enforcement for plant products was set as emamectin benzoate B1a, expressed as emamectin (Regulation (EU) No 396/2005); for risk assessment recently EFSA proposed the following residue definition: Sum of emamectin B1a, emamectin B1b, 8,9‐Z‐MAB1a, plus 3 times AB1a, plus 3 times MFB1a and 3 times FAB1a, expressed as emamectin (ongoing MRL review).

EFSA concluded that for the crops assessed in this application, metabolism of emamectin benzoate in primary crops and the possible degradation in processed products has been sufficiently addressed and that the previously derived residue definitions are applicable.

Sufficiently validated analytical methods based on liquid chromatography with tandem mass spectrometry (LC--MS/MS) are available to quantify residues in the crops assessed in this application according to the enforcement residue definition. The methods enable quantification of residues at or above 0.001 mg/kg in the crops assessed (LOQ).

The available residue trials are sufficient to derive MRL proposal of 0.15 mg/kg for kiwi and peaches.

Residues of emamectin benzoate in commodities of animal origin were not assessed since the crops under consideration in this MRL application are normally not fed to livestock.

The toxicological profile of emamectin benzoate was assessed in the framework of the EU pesticides peer review under Directive 91/414/EEC (EFSA, [2012](#efs25710-bib-0003){ref-type="ref"}) and the data were sufficient to derive an acceptable daily intake (ADI) of 0.0005 mg/kg body weight (bw) per day and an acute reference dose (ARfD) of 0.01 mg/kg bw. The metabolites included in the residue definition are of similar toxicity as the parent active substance.

The consumer risk assessment was performed with revision 2 of the EFSA Pesticide Residues Intake Model (PRIMo). The short‐term exposure did not exceed the ARfD for the crops assessed in this application. The estimated long‐term dietary intake was in the range of 15.2--93.9% of the ADI.

EFSA concluded that the proposed use of emamectin benzoate on kiwi and peaches will not result in a consumer exposure exceeding the toxicological reference values and therefore is unlikely to pose a risk to consumers' health.

EFSA proposes to amend the existing MRLs as reported in the summary table below.

Full details of all end points and the consumer risk assessment can be found in Appendices [B](#efs25710-sec-1002){ref-type="sec"}--[D](#efs25710-sec-1004){ref-type="sec"}.

Code[a](#efs25710-note-1006){ref-type="fn"}CommodityExisting EU MRL (mg/kg)Proposed EU MRL (mg/kg)Comment/justification**Enforcement residue definition:** Emamectin B1a benzoate, expressed as emamectin (Regulation (EU) No 396/2005)0162010Kiwi0.01[\*](#efs25710-note-1005){ref-type="fn"}0.15The submitted data are sufficient to derive a MRL proposal for the SEU use. Risk for consumers unlikely0140030Peaches0.030.15The submitted data are sufficient to derive a MRL proposal which is based on the more critical residue trials from NEU. Risk for consumers unlikely[^1][^2][^3]

Assessment {#efs25710-sec-0003}
==========

The detailed description of the intended uses of emamectin benzoate in peaches and kiwi, which are the basis for the current maximum residue level (MRL) application, is reported in Appendix [A](#efs25710-sec-1001){ref-type="sec"}.

Emamectin is the ISO common name for a mixture of emamectin B~1a~ (≥90%) and emamectin B~1b~ (≤ 10%): (10*E*,14*E*,16*E*,22*Z*)‐(*1R*,4*S*,5′*S*,6*S*,6′*R*,8*R*,12*S*,13*S*,20*R*,21*R*,24*S*)‐6′‐\[(*S*)‐*sec*‐butyl\]‐21,24‐dihydroxy‐5′,11,13,22‐tetramethyl‐2‐oxo‐(3,7,19‐trioxatetracyclo\[15.6.1.14,8.020,24\]pentacosa‐10,14,16,22‐tetraene)‐6‐spiro‐2′‐(5′,6′‐dihydro‐2′*H*‐pyran)‐12‐yl2,6‐dideoxy‐3‐*O*‐methyl‐4‐*O*‐(2,4,6‐trideoxy‐3‐*O*‐methyl‐4‐methylamino‐α‐[l]{.smallcaps}‐lyxo‐hexapyranosyl)‐α‐[l]{.smallcaps}‐arabino‐hexapyranoside;

and (10*E*,14*E*,16*E*,22*Z*)‐(1*R*,4*S*,5′*S*,6*S*,6′*R*,8*R*,12*S*,13*S*,20*R*,21*R*,24*S*)‐21,24‐dihydroxy‐6′‐isopropyl‐5′,11,13,22‐tetramethyl‐2‐oxo‐(3,7,19trioxatetracyclo\[15.6.1.14,8.020,24\]pentacosa‐10,14,16,22‐tetraene)‐6‐spiro‐2′‐(5′,6′‐dihydro‐2′*H*‐pyran)‐12‐yl2,6‐dideoxy‐3‐*O*‐methyl‐4‐*O*‐(2,4,6‐trideoxy‐3‐*O*‐methyl‐4‐methylamino‐α‐[l]{.smallcaps}‐lyxo‐hexapyranosyl)‐α‐[l]{.smallcaps}‐arabino‐hexapyranoside(*E*,*Z*)‐3‐(2‐chloro‐thiazol‐5‐ylmethyl)‐5‐methyl‐\[1,3,5\]oxadiazinan‐4‐ylidene‐*N*‐nitroamine; respectively (IUPAC).

The chemical structures of the active substance and its main metabolites are reported in Appendix [E](#efs25710-sec-1005){ref-type="sec"}.

Emamectin benzoate was evaluated in the framework of Directive 91/414/EEC[1](#efs25710-note-1007){ref-type="fn"} in accordance with Commission Regulation (EU) No 188/2011[2](#efs25710-note-1008){ref-type="fn"} with the Netherlands designated as rapporteur Member State (RMS) for the representative use as an insecticide after foliar applications on grapes, tomatoes, peppers, cucurbits and lettuces, outdoor and/or indoor, depending on the vegetable. The draft assessment report (DAR) prepared by the RMS (Netherlands, [2008](#efs25710-bib-0021){ref-type="ref"}, [2012](#efs25710-bib-0022){ref-type="ref"}) has been peer reviewed by European Food Safety Authority (EFSA, [2012](#efs25710-bib-0003){ref-type="ref"}). Emamectin benzoate was approved[3](#efs25710-note-1009){ref-type="fn"} for the use as insecticide on 1 May 2014.

The EU MRLs for emamectin benzoate are established in Annex IIIA of Regulation (EC) No 396/2005.[4](#efs25710-note-1010){ref-type="fn"} The review of existing MRLs according to Article 12 of Regulation (EC) No 396/2005 (MRL review) is currently ongoing. EFSA has previously issued reasoned opinions on the modification of MRLs for emamectin benzoate (EFSA [2009](#efs25710-bib-0001){ref-type="ref"}, [2011](#efs25710-bib-0002){ref-type="ref"}, [2018](#efs25710-bib-0004){ref-type="ref"}). The proposals from these reasoned opinions have been considered by revising the EU MRL legislation.[5](#efs25710-note-1011){ref-type="fn"} In 2013, certain Codex MRLs (CXLs) adopted by Codex Alimentarius Commission (CAC) in 2012 were implemented in the EU legislation.[6](#efs25710-note-1012){ref-type="fn"}

In accordance with Article 6 of Regulation (EC) No 396/2005, Syngenta submitted an application to the competent national authority in France (evaluating Member State, EMS‐FR) to modify the existing MRL for the active substance emamectin benzoate in peaches. The EMS‐FR drafted an evaluation report in accordance with Article 8 of Regulation (EC) No 396/2005 (France, [2015](#efs25710-bib-0019){ref-type="ref"}), which was submitted to the European Commission and forwarded to EFSA on 5 March 2015. To accommodate for the intended use of emamectin benzoate, the EMS‐FR proposed to raise the existing MRL from 0.03 mg/kg to 0.09 mg/kg.

A second request was submitted by Syngenta to the competent national authority in Italy (EMS‐IT) to modify the MRL emamectin benzoate in kiwi. The EMS‐IT drafted an evaluation report in accordance with Article 8 of Regulation (EC) No 396/2005 (Italy, [2015](#efs25710-bib-0020){ref-type="ref"}), which was submitted to the European Commission and forwarded to EFSA on 9 November 2015. To accommodate for the intended use of emamectin benzoate, the EMS‐IT proposed to raise the existing MRL of emamectin benzoate in kiwi from the limit of quantification (LOQ) of 0.01 mg/kg to 0.15 mg/kg.

EFSA assessed the application and the evaluation reports as required by Article 10 of the MRL regulation. EFSA identified data gaps, which were requested from both the EMSs France and Italy. On 11 December 2018 and 1 March 2019, France and Italy, respectively, submitted the requested information in revised evaluation reports, which replaced the previous versions.

EFSA based its assessment on the revised evaluation reports submitted by the EMS‐FR and the EMS‐IT (France, [2015](#efs25710-bib-0019){ref-type="ref"}; Italy, [2015](#efs25710-bib-0020){ref-type="ref"}), the DAR and its final addendum prepared under Directive 91/414/EEC (Netherlands, [2008](#efs25710-bib-0021){ref-type="ref"}, [2012](#efs25710-bib-0022){ref-type="ref"}), the conclusion on the peer review of the pesticide risk assessment of the active substance emamectin (EFSA, [2012](#efs25710-bib-0003){ref-type="ref"}), the European Commission review report on emamectin (European Commission, [2013](#efs25710-bib-0015){ref-type="ref"}), the JMPR Evaluation report (FAO, [2011](#efs25710-bib-0018){ref-type="ref"}), EFSA scientific reports and reasoned opinions (EFSA, [2009](#efs25710-bib-0001){ref-type="ref"}, [2011](#efs25710-bib-0002){ref-type="ref"}, [2018](#efs25710-bib-0004){ref-type="ref"}).

For this application, the data requirements established in Regulation (EU) No 544/2011[7](#efs25710-note-1013){ref-type="fn"} and the guidance documents applicable at the date of submission of the application to the EMS are applicable (European Commission, [1997a](#efs25710-bib-0005){ref-type="ref"},[b](#efs25710-bib-0006){ref-type="ref"},[c](#efs25710-bib-0007){ref-type="ref"},[d](#efs25710-bib-0008){ref-type="ref"},[e](#efs25710-bib-0009){ref-type="ref"},[f](#efs25710-bib-0010){ref-type="ref"},[g](#efs25710-bib-0011){ref-type="ref"}, [2000](#efs25710-bib-0012){ref-type="ref"}, [2010a](#efs25710-bib-0013){ref-type="ref"},[b](#efs25710-bib-0014){ref-type="ref"}, [2017](#efs25710-bib-0016){ref-type="ref"}; OECD, [2011](#efs25710-bib-0023){ref-type="ref"}, [2013](#efs25710-bib-0024){ref-type="ref"}). The assessment is performed in accordance with the legal provisions of the Uniform Principles for the Evaluation and the Authorisation of Plant Protection Products adopted by Commission Regulation (EU) No 546/2011.[8](#efs25710-note-1014){ref-type="fn"}

As the review of the existing MRLs under Article 12 of Regulation 396/2005 is not yet finalised, the conclusions reported in this reasoned opinion may need to be reconsidered in the light of the outcome of the MRL review.

A selected list of end points of the studies assessed by EFSA in the framework of this MRL application, including the end points of relevant studies assessed previously, are presented in Appendix [B](#efs25710-sec-1002){ref-type="sec"}.

The evaluation reports submitted by the EMS‐FR and EMS‐IT (France, [2015](#efs25710-bib-0019){ref-type="ref"}; Italy, [2015](#efs25710-bib-0020){ref-type="ref"}) and the exposure calculations using the EFSA Pesticide Residues Intake Model (PRIMo) are considered as supporting documents to this reasoned opinion and, thus, are made publicly available as background documents to this reasoned opinion.

1. Residues in plants {#efs25710-sec-0004}
=====================

1.1. Nature of residues and methods of analysis in plants {#efs25710-sec-0005}
---------------------------------------------------------

### 1.1.1. Nature of residues in primary crops {#efs25710-sec-0006}

The metabolism of emamectin B1a benzoate following foliar application was investigated in crops belonging to the groups of fruit crops, leafy crops and cereals/grass in the framework of the EU pesticides peer review (EFSA, [2012](#efs25710-bib-0003){ref-type="ref"}). Emamectin B~1a~ benzoate was extensively metabolised, forming a number photodegradation products which were mainly observed in leafy crops (lettuces and cabbages). Emamectin B~1a~ was the predominant compound (3--22% of total radioactive residue (TRR), at preharvest interval (PHI) ≤ 1 day). The different photodegradation products (also referred to as 'mectin‐like' fraction or photodegradation metabolites, consisting of e.g. 8,9‐Z‐MAB~1a~, FAB~1a~, MFB~1a~, AB~1a~) individually were present in low levels, but together represented significant amount (up to 20% of TRR). In fruit crops (pears), emamectin B~1a~ was the only compound identified; photodegradation metabolites were not identified in the fruits (EFSA, [2012](#efs25710-bib-0003){ref-type="ref"}).

For the intended use in kiwi and peaches, plant metabolism is considered to be sufficiently addressed.

### 1.1.2. Nature of residues in rotational crops {#efs25710-sec-0007}

Since kiwi and peaches are permanent crops, the assessment of the nature of residues in rotational crops was not required.

### 1.1.3. Nature of residues in processed commodities {#efs25710-sec-0008}

Standard hydrolysis studies simulating processing conditions representative of pasteurisation, boiling and sterilisation were assessed in the framework of the EU pesticides peer review (EFSA, [2012](#efs25710-bib-0003){ref-type="ref"}). The compound was found to degrade significantly under standard hydrolysis condition (ca. 20%) to MSB~1a~, AB~1a~ and several unknown compounds.

### 1.1.4. Methods of analysis in plants {#efs25710-sec-0009}

The EU pesticide peer review concluded that an analytical method using liquid chromatography with tandem mass spectrometry (LC--MS/MS) was sufficiently validated for one ion transition on high water, high acid and high oil content matrices, dry commodities and wheat straw with individual LOQ of 0.001 mg/kg for all components of the residue definition for monitoring and risk assessment (EFSA, [2012](#efs25710-bib-0003){ref-type="ref"}). Independent laboratory validation (ILV) was provided only for high water content commodities (EFSA, [2012](#efs25710-bib-0003){ref-type="ref"}). Confirmatory methods are available for all the above mentioned four groups of commodities (EFSA, [2018](#efs25710-bib-0004){ref-type="ref"}).

Thus, for kiwi and peaches, crops belonging to the crop group characterised as matrices with high acid and high water content, sufficiently validated analytical methods are available for enforcing the proposed MRL for emamectin.

### 1.1.5. Stability of residues in plants {#efs25710-sec-0010}

The storage stability of emamectin (B~1a~ and B~1b~) and its relevant photodegradation metabolites under frozen conditions (−20°C) was demonstrated for at least 18 months in high water‐ and dry/high starch content commodities (EFSA, [2012](#efs25710-bib-0003){ref-type="ref"}).

In the context of current application, the applicant submitted a new storage stability study in orange which is relevant for the setting of MRL in kiwi (Italy, [2015](#efs25710-bib-0020){ref-type="ref"}). This new study demonstrated that emamectin (B~1a~ and B~1b~) and its relevant photodegradation metabolites were stable at −18°C for at least 18 months in high acid content commodities.

### 1.1.6. Proposed residue definitions {#efs25710-sec-0011}

Based on the metabolism studies submitted in primary crops, rotational crops and the studies addressing the nature of residues in processed commodities, the following residue definitions have been used for the current MRL proposals:

Residue definition for enforcement:

Emamectin benzoate B~1a~, expressed as emamectin (Regulation (EU) No 396/2005)

Residue definition for risk assessment:

Sum of emamectin B~1a~, emamectin B~1b~, 8,9‐Z‐MAB~1a~, plus 3 times AB~1a~, plus 3 times MFB~1a~ and 3 times FAB~1a~, expressed as emamectin (EFSA, [2018](#efs25710-bib-0004){ref-type="ref"}).

The risk assessment residue definition was derived on a provisional basis, pending the finalisation of the MRL review. It is noted that the residue definitions (enforcement and risk assessment) will be revised following the MRL review under Article 12[9](#efs25710-note-1015){ref-type="fn"} of Regulation (EC) No 396/2005.

The MRL proposals derived in the framework of the current assessment (which are derived based on the existing residue definitions) may need to be reviewed, in case the residue definitions will be revised following the MRL review under Article 12 of Regulation (EC) No 396/2005.

1.2. Magnitude of residues in plants {#efs25710-sec-0012}
------------------------------------

### 1.2.1. Magnitude of residues in primary crops {#efs25710-sec-0013}

In support of the MRL applications, the applicants submitted residue trials performed in kiwi and peaches. All samples were analysed for all the components included in the residue definition for enforcement and risk assessment. According to the assessment of the EMS‐FR and EMS‐IT, the analytical methods used to analyse the residue trial samples were sufficiently validated and fit for purpose (France, [2015](#efs25710-bib-0019){ref-type="ref"}; Italy, [2015](#efs25710-bib-0020){ref-type="ref"}).

The samples of these residue trials were stored under conditions for which integrity of the samples has been demonstrated.

The available studies are sufficient to derive a MRL proposal for the crops under consideration.

**Kiwi**

(Southern Europe (SEU) Good Agricultural Practice (GAP): 3 × 19 g/ha (expressed as emamectin benzoate) at 7 days interval, PHI 7 days)

The applicant submitted eight SEU residue trials. All trials are decline studies which were performed with and without oil (0.25%) on the same plot. In each sample the residue concentration of each component of the residue definition for enforcement and risk assessment were measured at PHI 3, 7 and 14 days in each of the following portions: whole‐fruit, peel and flesh. In almost all portions, the residue levels of emamectin B~1b~ and photodegradation metabolites were below the LOQ.

Since the residue levels of trials treated with and without oil are comparable, the values from trials without oil were used for calculating MRL proposal and risk assessment values. Furthermore, EFSA followed the EMS approach selecting, when relevant, the highest residue level in the whole fruit even when the value was related to longer PHI than the one defined in the GAP.

**Peaches**

(SEU and northern Europe (NEU) GAP: 3 × 38 g/ha (expressed as emamectin benzoate) at 7 days interval, PHI 3 days)

The applicant submitted 12 residue trials (8 SEU and 4 NEU). For each trial, two different formulations were used: a soluble granule formulation containing 9.5 g/kg emamectin benzoate and another formulation containing in addition 0.25% w/v Heliosol as an adjuvant. The results indicate that the adjuvant does not have an effect on the residues levels. All trials are decline studies where the levels of each chemical part of the residue definition for enforcement and risk assessments were measured at PHI 1, 3, 7 and 14 days in the whole fruit. In most samples, the residue levels of emamectin B~1b~ and photodegradation metabolites were below the LOQ. The residue levels of trials treated without oil were higher than those with oil, particularly for NEU use. The values from trials without oil were used for calculating MRL proposal and risk assessment values.

The EMS (France, [2015](#efs25710-bib-0019){ref-type="ref"}) stated that the SEU and NEU data sets are statistically comparable and consequently the MRL proposal was derived from the pooled data set. However, EFSA calculated separate MRL proposals for SEU and NEU uses since different light exposures may impact the levels of photodegradation metabolites formed.

### 1.2.2. Magnitude of residues in rotational crops {#efs25710-sec-0014}

Kiwi and peaches are permanent crops and therefore studies on rotational crops are not required.

### 1.2.3. Magnitude of residues in processed commodities {#efs25710-sec-0015}

The residue trials in kiwi allowed deriving peeling factors (Italy, [2015](#efs25710-bib-0020){ref-type="ref"}) which provide evidence that the residues in the peeled fruit are lower than the residues in the unpeeled fruit.

### 1.2.4. Proposed MRLs {#efs25710-sec-0016}

The available residue trials are sufficient to derive MRL proposals for kiwi and peaches (Appendix [B.4](#efs25710-sec-1002){ref-type="sec"}). In Section [3](#efs25710-sec-0018){ref-type="sec"}, EFSA assessed whether residues on this crop resulting from the intended use are likely to pose a consumer health risk.

2. Residues in livestock {#efs25710-sec-0017}
========================

Not relevant as crops under consideration are not used for feed purposes.

3. Consumer risk assessment {#efs25710-sec-0018}
===========================

EFSA performed a dietary risk assessment using revision 2 of the EFSA PRIMo.

For further details on the exposure calculations, a screenshot of the Report sheet of the PRIMo is presented in Appendix [C](#efs25710-sec-1003){ref-type="sec"}.

**Short‐term (acute) dietary risk assessment**

The short‐term exposure assessment for emamectin was performed in accordance with the internationally agreed methodology. The calculation was based on the highest residue (HR) derived from supervised field trials submitted in the current application reflecting the residue definition for risk assessment (Appendix [D.1](#efs25710-sec-1004){ref-type="sec"}).

The short‐term exposure did not exceed the ARfD for any the crops assessed in this application (the estimated exposure for peaches and kiwis amounted to 47.5% and 32.2% of the ARfD, respectively).

**Long‐term (chronic) dietary risk assessment**

The calculation was based on the median residue concentration (STMR) derived from supervised field trials submitted in the current application, reflecting the residue definition for risk assessment. In addition, STMR values from previous published EFSA opinions (EFSA, [2009](#efs25710-bib-0001){ref-type="ref"}, [2011](#efs25710-bib-0002){ref-type="ref"}, [2018](#efs25710-bib-0004){ref-type="ref"}) and from FAO ([2011](#efs25710-bib-0018){ref-type="ref"}) were included in the dietary exposure assessment. Furthermore, for other food commodities of plant and animal origin the MRL currently implemented in EU Regulation 2018/1514 were also used. The MRL values were used considering that the MRL review for emamectin is ongoing and therefore to cover potential uses that are currently not considered. The complete list of input values used in the exposure calculations is presented Appendix [D.1](#efs25710-sec-1004){ref-type="sec"}.

The estimated long‐term dietary intake was in the range of 15.2--93.9% of the ADI. Peaches and kiwis contributed to a maximum of 3.4% and 1.6% of the ADI, respectively.

EFSA concluded that the long‐term intake of residues of emamectin resulting from the existing and the intended uses is unlikely to present a risk to consumer health.

4. Conclusion and Recommendations {#efs25710-sec-0019}
=================================

The data submitted in support of this MRL application were found to be sufficient to derive an MRL proposal for kiwi and peaches.

EFSA concluded that the proposed use of emamectin benzoate will not result in a consumer exposure exceeding the toxicological reference values and therefore is unlikely to pose a risk to consumers' health.

The MRL recommendations are summarised in Appendix [B.4](#efs25710-sec-1002){ref-type="sec"}.

Abbreviations {#efs25710-sec-0020}
=============

a.s.active substanceADIacceptable daily intakeARfDacute reference doseBBCHgrowth stages of mono‐ and dicotyledonous plantsbwbody weightCACCodex Alimentarius CommissionCFconversion factor for enforcement to risk assessment residue definitioncGAPcritical GAPCXLCodex maximum residue limitDARdraft assessment reportDATdays after treatmentECemulsifiable concentrateEMSevaluating Member Stateeqresidue expressed as a.s. equivalentFAOFood and Agriculture Organization of the United NationsGAPGood Agricultural PracticeHRhighest residueIEDIinternational estimated daily intakeIESTIinternational estimated short‐term intakeILVindependent laboratory validationInChiKeyInternational Chemical Identifier KeyISOInternational Organisation for StandardisationIUPACInternational Union of Pure and Applied ChemistryJMPRJoint FAO/WHO Meeting on Pesticide ResiduesLCliquid chromatographyLOQlimit of quantificationMRLmaximum residue levelMS/MStandem mass spectrometry detectorMWmolecular weightNEUnorthern EuropeOECDOrganisation for Economic Co‐operation and DevelopmentPBIplant‐back intervalPFprocessing factorPHIpre‐harvest intervalPRIMo(EFSA) Pesticide Residues Intake ModelRArisk assessmentRACraw agricultural commodityRDresidue definitionRMSrapporteur Member StateRPFrelative potency factorSANCODirectorate‐General for Health and ConsumersSEUsouthern EuropeSGwater‐soluble granuleSMILESsimplified molecular‐input line‐entry systemSTMRsupervised trials median residueTRRtotal radioactive residueWGwater‐dispersible granuleWHOWorld Health Organization

Appendix A -- Summary of intended GAP triggering the amendment of existing EU MRLs {#efs25710-sec-1001}
==================================================================================

 {#efs25710-sec-0021}

Crop and/or situationNEU, SEU, MS or countryF G or I[a](#efs25710-note-1017){ref-type="fn"}Pests or Group of pests controlledPreparationApplicationApplication rate per treatmentPHI (days) [d](#efs25710-note-1020){ref-type="fn"}RemarksType [b](#efs25710-note-1018){ref-type="fn"}Conc. a.s.Method kindRange of growth stages & season[c](#efs25710-note-1019){ref-type="fn"}Number min--maxInterval between application (min)g a.s./hL min--maxWater L/ha min--maxRateUnitPeachesNEU and SEU (NEU‐EU: SI, HU SEU‐EU : IT, GR)F*Laspeyresia molesta*,*Cydia molesta*,*Anarsia lineatella*SG9.5 g/kgFoliar sprayBBCH 69--8937--500--1,50038g a.s/ha3Application rate expressed as emamectin benzoate with and without oil (0.25%)KiwiSEUFLeafroller *Argyrotaenia ljungiana*WG9.5 g/kgFoliar sprayBBCH 71--89a) 37--500--1,50019g a.s/ha7Application rate expressed as emamectin benzoate max. total rate per crop/season: 19 g/ha with and without oil (0.25%)[^4][^5][^6][^7][^8]

Appendix B -- List of end points {#efs25710-sec-1002}
================================

B.1.. Residues in plants {#efs25710-sec-0022}
------------------------

### B.1.1.. Nature of residues and methods of analysis in plants {#efs25710-sec-0023}

#### B.1.1.1.. Metabolism studies, methods of analysis and residue definitions in plants {#efs25710-sec-0024}

**Primary crops** (available studies)**Crop groupsCropsApplicationsSampling** Fruit cropsPearsFoliar, 3 × 16.8 or 168 g/ha, interval 7 days2 DAT~1~; 14, 28 DAT~3~Leafy cropsLettuceFoliar, 8 × 16.8 or 84 g/ha, interval 7 days2 DAT~1~; 1, 3, 7, 10 DAT~8~Head cabbageFoliar, 8 × 16.8 or 84 g/ha, interval 7 days2 DAT~1~; 1, 3, 7, 10 DAT~8~Cereals/grassMaizeFoliar, 6 × 16.8 or 84 g/ha, interval 3‐5 days2 DAT~1~; 1, 3, 7 DAT~6~Comments: \[3, 7, 11, 13, 23‐^14^C\]‐emamectin B~1a~ benzoate or \[23‐^14^C\]‐emamectin B~1a~ benzoate (pear study) variant. Reference: EFSA ([2012](#efs25710-bib-0003){ref-type="ref"})**Rotational crops** (available studies)**Crop groupsCrop(s)Application(s)PBI** (DAT) Root/tuber cropsCarrotsBare soil, 6 × 168 g/ha, interval 7 days30, 141, 365Leafy cropsLettuceBare soil, 6 × 168 g/ha, interval 7 days30, 120, 365Cereal (small grain)BarleyBare soil, 6 × 168 g/ha, interval 7 days30, 141, 365Comments: \[3, 7, 11, 13, 23‐^14^C\]‐emamectin B~1a~ benzoate variant. Reference: EFSA ([2012](#efs25710-bib-0003){ref-type="ref"})**Processed commodities** (hydrolysis study)**ConditionsInvestigated** Pasteurisation (20 min, 90°C, pH 4)YesBaking, brewing and boiling (60 min, 100°C, pH 5)YesSterilisation (20 min, 120°C, pH 6)YesComment: \[23‐^14^C\]‐emamectin B~1a~ benzoate variant. Reference: EFSA ([2012](#efs25710-bib-0003){ref-type="ref"}) Emamectin B~1a~ benzoate underwent hydrolysis (ca 20%) forming the monosaccharide MSB~1a~ (pH 5, 100°C and pH 6, 120°C), aglycone milbemectin B (pH 6, 120°C) and AB~1a~ (pH 6, 120°C). All degradation products were individually \< 10% of applied radioactivity.[^9]

![](EFS2-17-e05710-g002.jpg "image")

#### B.1.1.2.. Stability of residues in plants {#efs25710-sec-0025}

Plant products (available studies)CategoryCommodityT (°C)Stability periodCompounds coveredComment/ SourceValueUnit High water contentTomato, Beans with pod−2018MonthsEmamectin B1a benzoate, Emamectin B1b benzoate, 8,9‐Z MAB1a, AB1a, MFB1a, and FAB1aEFSA ([2012](#efs25710-bib-0003){ref-type="ref"})Dry/High starchPotato−2018MonthsHigh acid contentWhole orange−1818MonthsItaly ([2015](#efs25710-bib-0020){ref-type="ref"})Processed products------------Others------------       

### B.1.2.. Magnitude of residues in plants {#efs25710-sec-0026}

#### B.1.2.1.. Summary of residues data from the supervised residue trials {#efs25710-sec-0027}

CommodityRegion/ Indoor[a](#efs25710-note-1024){ref-type="fn"}Residue levels observed in the supervised residue trials (mg/kg)Comments/SourceCalculated MRL (mg/kg)HR[b](#efs25710-note-1025){ref-type="fn"} (mg/kg)STMR[c](#efs25710-note-1026){ref-type="fn"} (mg/kg)CF[d](#efs25710-note-1027){ref-type="fn"}**Residue definition for enforcement**: Emamectin benzoate B1a, expressed as emamectin (Regulation (EU) No 396/2005) (residue definition may change in the light of the outcome of the MRL review) **Residue definition for risk assessment:** Sum of emamectin B1a, emamectin B1b, 8,9‐Z‐MAB1a, plus 3 times AB1a, plus 3 times MFB1a and 3 times FAB1a, expressed as emamectin (France, [2015](#efs25710-bib-0019){ref-type="ref"}; EFSA, [2018](#efs25710-bib-0004){ref-type="ref"}) (provisionally, residue definition to be reconsidered in the light of the outcome of the MRL review) **Note:** [For monitoring]{.ul}, the individual residue values of emamectin B~1a~ benzoate was recalculated to the emamectin B~1a~ free base by adjusting for the molecular weight. In addition, the residue level of Emamectin B~1b~ (expressed as free base) was summed up. [For risk assessment]{.ul}, same as for monitoring and in addition the photodegradation metabolites were expressed as emamectin by using the following procedure: 8,9‐Z‐MBA1was adjusted using a MW conversion factor (CF) of 1; MFB1a was first adjusted with a MW CF of 0.97 and then by a relative potency factor (RPF) of 3; FAB1a was first adjusted with a MW CF of 0.98 and then by a RPF of 3; AB1a was first adjusted with a MW CF of 1.02 and then by a RPF of 3. Ultimately, all the calculated values, described as above, were summed up.**Note 1:** The corresponding MRL proposals for the residue definition agreed in the draft Art 12 Reasoned Opinion are identical to the ones presented in the tale below.KiwiSEU (outdoor without oil)**Mo:** 0.006, 0.010, 0.010, [0.020]{.ul}, 0.022, 0.036, [0.045]{.ul}, 0.067 **RA:** 0.016, 0.020, 0.020, [0.030]{.ul}, 0.032, 0.046, [0.055]{.ul}, 0.077Residue trials on kiwi compliant with SEU GAP. Values underlined refer to a PHI of 14 days and they were used since they were higher than values measured at PHI of 7 days (which represent the cGAP). Trials performed with oil (0.25%) do not have impact neither on MRL nor on risk assessment. Therefore, residue values from trials without oil were used for calculating MRL proposal and risk assessment values**0.15Mo:** 0.07 **RA:** 0.08**Mo:** 0.02 **RA:** 0.03-- SEU (outdoor with oil)**Mo:** 0.010, [0.011]{.ul}, 0.011, 0.024, 0.026, [0.048]{.ul}, 0.055, [0.074]{.ul} **RA:** 0.020, [0.021]{.ul}, 0.021, 0.034, 0.036, [0.058]{.ul}, 0.065, [0.084]{.ul}**0.15Mo:** 0.07 **RA:** 0.08**Mo:** 0.03 **RA:** 0.03--PeachesSEU (outdoor without oil)**Mo:** 0.003, 0.003, 0.004, 0.006, 0.011, 0.013, 0.022, 0.026 **RA:** 0.013, 0.013, 0.013, 0.016, 0.020, 0.023, 0.034, 0.039Residue trials on peaches compliant with SEU GAP The use of oil (0.25%) has limited impact on MRL and on risk assessment. Therefore, residue values from trials without oil were used for calculating MRL proposal and risk assessment values**0.05Mo:** 0.03 **RA:** 0.04**Mo:** 0.01 **RA:** 0.02-- SEU (outdoor with oil)**Mo:** 0.004, 0.004, 0.007, 0.010, 0.013, 0.014, 0.022, 0.022 **RA:** 0.013, 0.017, 0.017, 0.024, 0.025, 0.035, 0.039, 0.044**0.04Mo:** 0.02 **RA:** 0.04**Mo:** 0.01 **RA:** 0.02-- NEU (outdoor without oil)**Mo:** 0.014, 0.017, 0.021, 0.071 **RA:** 0.030, 0.033, 0.034, 0.081Residue trials on peaches compliant with NEU GAP The use of oil (0.25%) leads to lower MRLs and risk assessment values. Therefore, residue values from trials without oil were used for calculating MRL proposal and risk assessment values**0.15Mo:** 0.07 **RA:** 0.08**Mo:** 0.02 **RA:** 0.03-- NEU (outdoor with oil)**Mo:** 0.004, 0.006, 0.011, 0.012 **RA:** 0.016, 0.016, 0.022, 0.044**0.03Mo:** 0.01 **RA:** 0.04**Mo:** 0.01 **RA:** 0.02--[^10][^11][^12][^13][^14][^15]

#### B.1.2.2.. Residues in rotational crops {#efs25710-sec-0028}

![](EFS2-17-e05710-g003.jpg "image")

#### B.1.2.3.. Processing factors {#efs25710-sec-0029}

Processed commodityNumber of validstudies[a](#efs25710-note-1028){ref-type="fn"}Processing Factor (PF)CF~P~ [b](#efs25710-note-1029){ref-type="fn"}Comment/SourceIndividual valuesMedian PFKiwi, pulp80.03, 0.09, 0.07, 0.18, 0.04, 0.08, 0.18, 0.290.0814.3Italy ([2015](#efs25710-bib-0020){ref-type="ref"})[^16][^17]

B.2.. Residues in livestock {#efs25710-sec-0030}
---------------------------

Not relevant

B.3.. Consumer risk assessment {#efs25710-sec-0031}
------------------------------

![](EFS2-17-e05710-g004.jpg "image")

![](EFS2-17-e05710-g005.jpg "image")

B.4.. **Recommended MRLs** {#efs25710-sec-0032}
--------------------------

Code[a](#efs25710-note-1032){ref-type="fn"}CommodityExisting EU MRL (mg/kg)Proposed EU MRL (mg/kg)Comment/justification**Enforcement residue definition:** Emamectin B1a benzoate, expressed as emamectin (Regulation (EU) No 396/2005)0162010Kiwi0.01[\*](#efs25710-note-1031){ref-type="fn"}0.15The submitted data are sufficient to derive a MRL proposal for the SEU use. Risk for consumers unlikely0140030Peaches0.030.15The submitted data are sufficient to derive a MRL proposal which is based on the more critical residue trials from NEU. Risk for consumers unlikely[^18][^19][^20]

Appendix C -- Pesticide Residue Intake Model (PRIMo) {#efs25710-sec-1003}
====================================================

 {#efs25710-sec-0033}

Appendix D -- Input values for the exposure calculations {#efs25710-sec-1004}
========================================================

D.1.. Consumer risk assessment {#efs25710-sec-0034}
------------------------------

CommodityChronic risk assessmentAcute risk assessmentInput value (mg/kg)CommentInput value (mg/kg)CommentKiwi0.03STMR~RA~0.08HR~RA~Peaches0.03STMR~RA~ (NEU use)0.08HR~RA~ (NEU use)Citrus fruit0.003STMR~Mo~ (EFSA, [2011](#efs25710-bib-0002){ref-type="ref"})[a](#efs25710-note-1034){ref-type="fn"}Acute risk assessment is performed only for the crops under assessmentPome fruit0.005STMR~Mo~ (EFSA, [2009](#efs25710-bib-0001){ref-type="ref"})[a](#efs25710-note-1034){ref-type="fn"}Apricots0.008STMR~Mo~ (EFSA, [2011](#efs25710-bib-0002){ref-type="ref"})[a](#efs25710-note-1034){ref-type="fn"}Plums0.003STMR~Mo~ (EFSA, [2011](#efs25710-bib-0002){ref-type="ref"})[a](#efs25710-note-1034){ref-type="fn"}Table grapes0.0025STMR~Mo~ (FAO, [2011](#efs25710-bib-0018){ref-type="ref"})[b](#efs25710-note-1035){ref-type="fn"}Wine grapes0.0025STMR~Mo~ (FAO, [2011](#efs25710-bib-0018){ref-type="ref"})[b](#efs25710-note-1035){ref-type="fn"}Strawberries0.009STMR~Mo~ (EFSA, [2009](#efs25710-bib-0001){ref-type="ref"})[a](#efs25710-note-1034){ref-type="fn"}Tomatoes0.006STMR~Mo~ (EFSA, [2009](#efs25710-bib-0001){ref-type="ref"})[a](#efs25710-note-1034){ref-type="fn"}Peppers0.003STMR~Mo~ (EFSA, [2009](#efs25710-bib-0001){ref-type="ref"})[a](#efs25710-note-1034){ref-type="fn"}Aubergines0.002STMR~Mo~ (EFSA, [2009](#efs25710-bib-0001){ref-type="ref"})[a](#efs25710-note-1034){ref-type="fn"}Cucurbits‐edible peel0.001STMR~Mo~ (EFSA, [2009](#efs25710-bib-0001){ref-type="ref"})[a](#efs25710-note-1034){ref-type="fn"}Cucurbits‐inedible peel0.002STMR~Mo~ (EFSA, [2009](#efs25710-bib-0001){ref-type="ref"})[a](#efs25710-note-1034){ref-type="fn"}Broccoli0.001STMR~Mo~ (EFSA, [2009](#efs25710-bib-0001){ref-type="ref"})[a](#efs25710-note-1034){ref-type="fn"}Cauliflower0.001STMR~Mo~ (EFSA, [2009](#efs25710-bib-0001){ref-type="ref"})[a](#efs25710-note-1034){ref-type="fn"}Head cabbage0.001STMR~Mo~ (EFSA, [2009](#efs25710-bib-0001){ref-type="ref"})[a](#efs25710-note-1034){ref-type="fn"}Chinese cabbage0.017STMR~RA~ (EFSA, [2018](#efs25710-bib-0004){ref-type="ref"})[c](#efs25710-note-1036){ref-type="fn"}Kale0.017STMR~RA~ (EFSA, [2018](#efs25710-bib-0004){ref-type="ref"})[c](#efs25710-note-1036){ref-type="fn"}Other leafy brassica0.017STMR~RA~ (EFSA, [2018](#efs25710-bib-0004){ref-type="ref"})[c](#efs25710-note-1036){ref-type="fn"}Lettuces and other salad plantsexcept scarole0.272STMR~Mo~ (EFSA, [2009](#efs25710-bib-0001){ref-type="ref"})[a](#efs25710-note-1034){ref-type="fn"}Scarole0.03STMR~Mo~ (EFSA, [2009](#efs25710-bib-0001){ref-type="ref"})[a](#efs25710-note-1034){ref-type="fn"}Herbs and edible flowers0.272STMR~Mo~ (EFSA, [2009](#efs25710-bib-0001){ref-type="ref"})[a](#efs25710-note-1034){ref-type="fn"}Beans (with pods)0.017STMR~RA~ (EFSA, [2018](#efs25710-bib-0004){ref-type="ref"})[c](#efs25710-note-1036){ref-type="fn"}Peas (with pods)0.017STMR~RA~ (EFSA, [2018](#efs25710-bib-0004){ref-type="ref"})[c](#efs25710-note-1036){ref-type="fn"}Globe artichokes0.027STMR~Mo~ (EFSA, [2009](#efs25710-bib-0001){ref-type="ref"})[a](#efs25710-note-1034){ref-type="fn"}Mammalian meat[d](#efs25710-note-1037){ref-type="fn"}0.002STMR~Mo~ (FAO, [2011](#efs25710-bib-0018){ref-type="ref"})[b](#efs25710-note-1035){ref-type="fn"}Mammalian fat[d](#efs25710-note-1037){ref-type="fn"}0.002STMR~Mo~ (FAO, [2011](#efs25710-bib-0018){ref-type="ref"})[b](#efs25710-note-1035){ref-type="fn"}Mammalian liver[d](#efs25710-note-1037){ref-type="fn"}0.006STMR~Mo~ (FAO, [2011](#efs25710-bib-0018){ref-type="ref"})[b](#efs25710-note-1035){ref-type="fn"}Mammalian kidney[d](#efs25710-note-1037){ref-type="fn"}0.006STMR~Mo~ (FAO, [2011](#efs25710-bib-0018){ref-type="ref"})[b](#efs25710-note-1035){ref-type="fn"}Mammalian edible offal[d](#efs25710-note-1037){ref-type="fn"}0.006STMR~Mo~ (FAO, [2011](#efs25710-bib-0018){ref-type="ref"})[b](#efs25710-note-1035){ref-type="fn"}Milk and cream products0.0005STMR~Mo~ (FAO, [2011](#efs25710-bib-0018){ref-type="ref"})[b](#efs25710-note-1035){ref-type="fn"}Other food commodities ofplant and animal originMRLRegulation (EU) No 2018/1514[^21][^22][^23][^24][^25]

Appendix E -- Used compound codes {#efs25710-sec-1005}
=================================

 {#efs25710-sec-0035}

Code/trivial nameIUPAC name/SMILES notation/InChiKey[a](#efs25710-note-1039){ref-type="fn"}Structural formula[b](#efs25710-note-1040){ref-type="fn"}emamectin B~1a~(10*E*,14*E*,16*E*)‐(1*R*,4*S*,5′*S*,6*S*,6′*R*,8*R*,12*S*,13*S*,20*R*,21*R*,24*S*)‐6′‐\[(*S*)‐*sec*‐butyl\]‐21,24‐dihydroxy‐5′,11,13,22‐tetramethyl‐2‐oxo‐(3,7,19‐trioxatetracyclo\[15.6.1.1^4,8^.0^20,24^\]pentacosa‐10,14,16,22‐tetraene)‐6‐spiro‐2′‐(5′,6′‐dihydro‐2′*H*‐pyran)‐12‐yl 2,6‐dideoxy‐3‐*O*‐methyl‐4‐*O*‐(2,4,6‐trideoxy‐3‐*O*‐methyl‐4‐methylamino‐α‐[l]{.smallcaps}‐*lyxo*‐hexapyranosyl)‐α‐[l]{.smallcaps}‐*arabino*‐hexapyranoside CO\[C\@H\]1C\[C@\@H\](O\[C@\@H\](C)\[C\@H\]1NC)O\[C@\@H\]2\[C@\@H\](OC)C\[C@\@H\](O\[C\@H\]2C)O\[C@\@H\]3C(C)=CC\[C@\@H\]6C\[C\@H\](OC(=O)\[C@\@H\]4C=C(C)\[C@\@H\](O)\[C\@H\]5OCC(=CC=C\[C@\@H\]3C)\[C@@\]45O)C\[C@@\]7(O6)C=C\[C\@H\](C)\[C\@H\](O7)\[C@\@H\](C)CC CXEGAUYXQAKHKJ‐COFQVFHOSA‐N![](EFS2-17-e05710-g006.jpg "image")emamectin B~1b~(10*E*,14*E*,16*E*)‐(1*R*,4*S*,5′*S*,6*S*,6′*R*,8*R*,12*S*,13*S*,20*R*,21*R*,24*S*)‐21,24‐dihydroxy‐6′‐isopropyl‐5′,11,13,22‐tetramethyl‐2‐oxo‐(3,7,19‐trioxatetracyclo\[15.6.1.1^4,8^.0^20,24^\]pentacosa‐10,14,16,22‐tetraene)‐6‐spiro‐2′‐(5′,6′‐dihydro‐2′*H*‐pyran)‐12‐yl 2,6‐dideoxy‐3‐*O*‐methyl‐4‐*O*‐(2,4,6‐trideoxy‐3‐*O*‐methyl‐4‐methylamino‐α‐[l]{.smallcaps}‐*lyxo*‐hexapyranosyl)‐α‐[l]{.smallcaps}‐*arabino*‐hexapyranoside CO\[C\@H\]1C\[C@\@H\](O\[C@\@H\](C)\[C\@H\]1NC)O\[C@\@H\]2\[C@\@H\](OC)C\[C@\@H\](O\[C\@H\]2C)O\[C@\@H\]3C(C)=CC\[C@\@H\]6C\[C\@H\](OC(=O)\[C@\@H\]4C=C(C)\[C@\@H\](O)\[C\@H\]5OCC(=CC=C\[C@\@H\]3C)\[C@@\]45O)C\[C@@\]7(O6)C=C\[C\@H\](C)\[C\@H\](O7)C(C)C DXIOOXFZLKCVHK‐VAUHGISYSA‐N![](EFS2-17-e05710-g007.jpg "image")emamectin B~1a~ benzoate(10*E*,14*E*,16*E*)‐(1*R*,4*S*,5′*S*,6*S*,6′*R*,8*R*,12*S*,13*S*,20*R*,21*R*,24*S*)‐6′‐\[(*S*)‐*sec*‐butyl\]‐21,24‐dihydroxy‐5′,11,13,22‐tetramethyl‐2‐oxo‐(3,7,19‐trioxatetracyclo\[15.6.1.1^4,8^.0^20,24^\]pentacosa‐10,14,16,22‐tetraene)‐6‐spiro‐2′‐(5′,6′‐dihydro‐2′*H*‐pyran)‐12‐yl 2,6‐dideoxy‐3‐*O*‐methyl‐4‐*O*‐(2,4,6‐trideoxy‐3‐*O*‐methyl‐4‐methylamino‐α‐[l]{.smallcaps}‐*lyxo*‐hexapyranosyl)‐α‐[l]{.smallcaps}‐*arabino*‐hexapyranosidebenzoate O=C(O)c1ccccc1.CO\[C\@H\]1C\[C@\@H\](O\[C@\@H\](C)\[C\@H\]1NC)O\[C@\@H\]2\[C@\@H\](OC)C\[C@\@H\](O\[C\@H\]2C)O\[C@\@H\]3C(C)=CC\[C@\@H\]6C\[C\@H\](OC(=O)\[C@\@H\]4C=C(C)\[C@\@H\](O)\[C\@H\]5OCC(=CC=C\[C@\@H\]3C)\[C@@\]45O)C\[C@@\]7(O6)C=C\[C\@H\](C)\[C\@H\](O7)\[C@\@H\](C)CC GCKZANITAMOIAR‐PEZUHFCHSA‐N![](EFS2-17-e05710-g008.jpg "image")emamectin B~1b~ benzoate(10*E*,14*E*,16*E*)‐(1*R*,4*S*,5′*S*,6*S*,6′*R*,8*R*,12*S*,13*S*,20*R*,21*R*,24*S*)‐21,24‐dihydroxy‐6′‐isopropyl‐5′,11,13,22‐tetramethyl‐2‐oxo‐(3,7,19‐trioxatetracyclo\[15.6.1.1^4,8^.0^20,24^\]pentacosa‐10,14,16,22‐tetraene)‐6‐spiro‐2′‐(5′,6′‐dihydro‐2′*H*‐pyran)‐12‐yl 2,6‐dideoxy‐3‐*O*‐methyl‐4‐*O*‐(2,4,6‐trideoxy‐3‐*O*‐methyl‐4‐methylamino‐α‐[l]{.smallcaps}‐*lyxo*‐hexapyranosyl)‐α‐[l]{.smallcaps}‐*arabino*‐hexapyranoside benzoate O=C(O)c1ccccc1.CO\[C\@H\]1C\[C@\@H\](O\[C@\@H\](C)\[C\@H\]1NC)O\[C@\@H\]2\[C@\@H\](OC)C\[C@\@H\](O\[C\@H\]2C)O\[C@\@H\]3C(C)=CC\[C@\@H\]6C\[C\@H\](OC(=O)\[C@\@H\]4C=C(C)\[C@\@H\](O)\[C\@H\]5OCC(=CC=C\[C@\@H\]3C)\[C@@\]45O)C\[C@@\]7(O6)C=C\[C\@H\](C)\[C\@H\](O7)C(C)C ISGYOHXFFCGHKT‐WVYDVIEQSA‐N![](EFS2-17-e05710-g009.jpg "image")8,9‐Z‐MAB~1a~ NOA 438376(1'*R*,2*S*,4'*S*,5*S*,6*R*,8'*R*,10'*E*,12'*S*,13'*R*,14'*E*,16'*Z*,20'*R*,21'*R*,24'*S*)‐6‐\[(2*S*)‐butan‐2‐yl\]‐21',24'‐dihydroxy‐5,11',13',22'‐tetramethyl‐2'‐oxo‐5,6‐dihydrospiro\[pyran‐2,6'‐\[3,7,19\]trioxatetracyclo\[15.6.1.1^4,8^.0^20,24^\]pentacosa\[10,14,16,22\]tetraen\]‐12'‐yl 2,6‐dideoxy‐3‐*O*‐methyl‐4‐*O*‐\[2,4,6‐trideoxy‐3‐*O*‐methyl‐4‐(methylamino)‐a‐[l]{.smallcaps}‐*lyxo*‐hexopyranosyl\]‐a‐[l]{.smallcaps}‐*arabino*‐hexopyranoside CO\[C\@H\]1C\[C@\@H\](O\[C@\@H\](C)\[C\@H\]1NC)O\[C@\@H\]2\[C@\@H\](OC)C\[C@\@H\](O\[C\@H\]2C)O\[C@\@H\]3C(C)=CC\[C@\@H\]6C\[C\@H\](OC(=O)\[C@\@H\]4C=C(C)\[C@\@H\](O)\[C\@H\]5OCC(=CC=C\[C\@H\]3C)\[C@@\]45O)C\[C@@\]7(O6)C=C\[C\@H\](C)\[C\@H\](O7)\[C@\@H\](C)CC CXEGAUYXQAKHKJ‐ITVRGKHNSA‐N![](EFS2-17-e05710-g010.jpg "image")FAB~1a~ NOA 415693(1'*R*,2*S*,4'*S*,5*S*,6*R*,8'*R*,10'*E*,12'*S*,13'*S*,14'*E*,16'*E*,20'*R*,21'*R*,24'*S*)‐6‐\[(2*S*)‐butan‐2‐yl\]‐21',24'‐dihydroxy‐5,11',13',22'‐tetramethyl‐2'‐oxo‐5,6‐dihydrospiro\[pyran‐2,6'‐\[3,7,19\]trioxatetracyclo\[15.6.1.1^4,8^.0^20,24^\]pentacosa\[10,14,16,22\]tetraen\]‐12'‐yl 2,6‐dideoxy‐3‐*O*‐methyl‐4‐*O*‐(2,4,6‐trideoxy‐4‐formamido‐3‐*O*‐methyl‐a‐[l]{.smallcaps}‐*lyxo*‐hexopyranosyl)‐a‐[l]{.smallcaps}‐*arabino*‐hexopyranoside CO\[C\@H\]1C\[C@\@H\](O\[C@\@H\](C)\[C\@H\]1NC=O)O\[C@\@H\]2\[C@\@H\](OC)C\[C@\@H\](O\[C\@H\]2C)O\[C@\@H\]3C(C)=CC\[C@\@H\]6C\[C\@H\](OC(=O)\[C@\@H\]4C=C(C)\[C@\@H\](O)\[C\@H\]5OCC(=CC=C\[C@\@H\]3C)\[C@@\]45O)C\[C@@\]7(O6)C=C\[C\@H\](C)\[C\@H\](O7)\[C@\@H\](C)CC CTOLTUCVXLWGDP‐RTHKNZFHSA‐N![](EFS2-17-e05710-g011.jpg "image")MFB~1a~ NOA 415692(1'*R*,2*S*,4'*S*,5*S*,6*R*,8'*R*,10'*E*,12'*S*,13'*S*,14'*E*,16'*E*,20'*R*,21'*R*,24'*S*)‐6‐\[(2*S*)‐butan‐2‐yl\]‐21',24'‐dihydroxy‐5,11',13',22'‐tetramethyl‐2'‐oxo‐5,6‐dihydrospiro\[pyran‐2,6'‐\[3,7,19\]trioxatetracyclo\[15.6.1.1^4,8^.0^20,24^\]pentacosa\[10,14,16,22\]tetraen\]‐12'‐yl 2,6‐dideoxy‐3‐*O*‐methyl‐4‐*O*‐{2,4,6‐trideoxy‐4‐\[formyl(methyl)amino\]‐3‐*O*‐methyl‐a‐[l]{.smallcaps}‐*lyxo*‐hexopyranosyl}‐a‐[l]{.smallcaps}‐*arabino*‐hexopyranoside O=CN(C)\[C\@H\]1\[C@\@H\](OC)C\[C@\@H\](O\[C\@H\]1C)O\[C@\@H\]2\[C@\@H\](OC)C\[C@\@H\](O\[C\@H\]2C)O\[C@\@H\]3C(C)=CC\[C@\@H\]6C\[C\@H\](OC(=O)\[C@\@H\]4C=C(C)\[C@\@H\](O)\[C\@H\]5OCC(=CC=C\[C@\@H\]3C)\[C@@\]45O)C\[C@@\]7(O6)C=C\[C\@H\](C)\[C\@H\](O7)\[C@\@H\](C)CC BNYCLYCAMIDELK‐OCAZNRKKSA‐N![](EFS2-17-e05710-g012.jpg "image")AB~1a~ NOA 438309(1'*R*,2*S*,4'*S*,5*S*,6*R*,8'*R*,10'*E*,12'*S*,13'*S*,14'*E*,16'*E*,20'*R*,21'*R*,24'*S*)‐6‐\[(2*S*)‐butan‐2‐yl\]‐21',24'‐dihydroxy‐5,11',13',22'‐tetramethyl‐2'‐oxo‐5,6‐dihydrospiro\[pyran‐2,6'‐\[3,7,19\]trioxatetracyclo\[15.6.1.1^4,8^.0^20,24^\]pentacosa\[10,14,16,22\]tetraen\]‐12'‐yl 4‐*O*‐(4‐amino‐2,4,6‐trideoxy‐3‐*O*‐methyl‐a‐[l]{.smallcaps}‐*lyxo*‐hexopyranosyl)‐2,6‐dideoxy‐3‐*O*‐methyl‐a‐[l]{.smallcaps}‐*arabino*‐hexopyranoside CO\[C\@H\]1C\[C@\@H\](O\[C@\@H\](C)\[C\@H\]1N)O\[C@\@H\]2\[C@\@H\](OC)C\[C@\@H\](O\[C\@H\]2C)O\[C@\@H\]3C(C)=CC\[C@\@H\]6C\[C\@H\](OC(=O)\[C@\@H\]4C=C(C)\[C@\@H\](O)\[C\@H\]5OCC(=CC=C\[C@\@H\]3C)\[C@@\]45O)C\[C@@\]7(O6)C=C\[C\@H\](C)\[C\@H\](O7)\[C@\@H\](C)CC WDJBWFOPQSVCHG‐RJHRBHNNSA‐N![](EFS2-17-e05710-g013.jpg "image")MSB~1a~ NOA 419150(1'*R*,2*S*,4'*S*,5*S*,6*R*,8'*R*,10'*E*,12'*S*,13'*S*,14'*E*,16'*E*,20'*R*,21'*R*,24'*S*)‐6‐\[(2*S*)‐butan‐2‐yl\]‐21',24'‐dihydroxy‐5,11',13',22'‐tetramethyl‐2'‐oxo‐5,6‐dihydrospiro\[pyran‐2,6'‐\[3,7,19\]trioxatetracyclo\[15.6.1.1^4,8^.0^20,24^\]pentacosa\[10,14,16,22\]tetraen\]‐12'‐yl 2,6‐dideoxy‐3‐*O*‐methyl‐a‐[l]{.smallcaps}‐*arabino*‐hexopyranoside C\[C@\@H\](CC)\[C\@H\]6O\[C@\]5(O\[C\@H\]2C\[C\@H\](OC(=O)\[C@\@H\]3C=C(C)\[C@\@H\](O)\[C\@H\]4OCC(=CC=C\[C\@H\](C)\[C\@H\](O\[C\@H\]1C\[C\@H\](OC)\[C@\@H\](O)\[C\@H\](C)O1)C(C)=CC2)\[C@@\]34O)C5)C=C\[C@\@H\]6C ZBVWYDMYMRLKIV‐OESCZRLOSA‐N![](EFS2-17-e05710-g014.jpg "image")Aglycone milbemectin B NOA 419153(1'*R*,2*S*,4'*S*,5*S*,6*R*,8'*R*,10'*E*,12'*S*,13'*S*,14'*E*,16'*E*,20'*R*,21'*R*,24'*S*)‐6‐\[(2*S*)‐butan‐2‐yl\]‐12',21',24'‐trihydroxy‐5,11',13',22'‐tetramethyl‐5,6‐dihydro‐2'*H*‐spiro\[pyran‐2,6'‐\[3,7,19\]trioxatetracyclo\[15.6.1.1^4,8^.0^20,24^\]pentacosa\[10,14,16,22\]tetraen\]‐2'‐one C\[C@\@H\](CC)\[C\@H\]5O\[C@\]4(O\[C\@H\]1C\[C\@H\](OC(=O)\[C@\@H\]2C=C(C)\[C@\@H\](O)\[C\@H\]3OCC(=CC=C\[C\@H\](C)\[C\@H\](O)C(C)=CC1)\[C@@\]23O)C4)C=C\[C@\@H\]5C XLEUIYGDSWMLCR‐AOIHNFKZSA‐N![](EFS2-17-e05710-g015.jpg "image")[^26][^27][^28]

Council Directive 91/414/EEC of 15 July 1991 concerning the placing of plant protection products on the market. OJ L 230, 19.8.1991, p. 1--32.

Commission Regulation (EU) No 188/2011 of 25 February 2011 laying down detailed rules for the implementation of Council Directive 91/414/EEC as regards the procedure for the assessment of active substances which were not on the market 2 years after the date of notification of that Directive. OJ L 53, 26.2.2011, p. 51--55.

Commission Implementing Regulation (EU) No 828/2013 of 29 August 2013 approving the active substance emamectin, in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market, and amending the Annex to Commission Implementing Regulation (EU) No 540/2011.OJ L 232, 30.8.2013, p. 23--28.

Regulation (EC) No 396/2005 of the Parliament and of the Council of 23 February 2005 on maximum residue levels of pesticides in or on food and feed of plant and animal origin and amending Council Directive 91/414/EEC. OJ L 70, 16.3.2005, p. 1--16.

For an overview of all MRL Regulations on this active substance, please consult: <http://ec.europa.eu/food/plant/pesticides/eu-pesticides-database/public/?event=pesticide.residue.selection&language=EN>

Commission Regulation EU) No 293/2013 of 20 March 2013 amending Annexes II and III to Regulation (EC) No 396/2005 of the European Parliament and of the Council as regards maximum residue levels for emamectin benzoate, etofenprox, etoxazole, flutriafol, glyphosate, phosmet, pyraclostrobin, spinosad and spirotetramat in or on certain products. OJ L 96, 5.4.2013, p. 1--30.

Commission Regulation (EU) No 544/2011 of 10 June 2011 implementing Regulation (EC) No 1107/2009 of the European Parliament and of the Council as regards the data requirements for active substances. OJ L 155, 11.6.2011, p. 1--66.

Commission Regulation (EU) No 546/2011 of 10 June 2011 implementing Regulation (EC) No 1107/2009 of the European Parliament and of the Council as regards uniform principles for evaluation and authorisation of plant protection products. OJ L 155, 11.6.2011, p. 127--175.

In the Member States consultation on the draft Art 12 Reasoned Opinion the following new residue definitions were agreed:

Enforcement: Emamectin B1a and its salts, expressed as emamectin B1a (free base); Risk assessment: Sum of emamectin B1a, emamectin B1b, 8,9‐Z‐MAB1a, plus 3 times AB1a, plus 3 times MFB1a and 3 times FAB1a, expressed as emamectin B1a (free base).

[^1]: MRL: maximum residue level; SEU: southern Europe; NEU: northern Europe.

[^2]: Indicates that the MRL is set at the limit of analytical quantification (LOQ).

[^3]: Commodity code number according to Annex I of Regulation (EC) No 396/2005.

[^4]: GAP: Good Agricultural Practice; MRL: maximum residue level; NEU: northern European Union; SEU: southern European Union; MS: Member State; a.s.: active substance; SG: water‐soluble granule; WG: water‐dispersible granule.

[^5]: Outdoor or field use (F), greenhouse application (G) or indoor application (I).

[^6]: CropLife International Technical Monograph no 2, 6th Edition. Revised May 2008. Catalogue of pesticide formulation types and international coding system.

[^7]: Growth stage range from first to last treatment (BBCH Monograph, Growth Stages of Plants, 1997, Blackwell, ISBN 3‐8263‐3152‐4), including, where relevant, information on season at time of application.

[^8]: PHI: minimum preharvest interval.

[^9]: DAT~1~, DAT~n~, days after the first, days after nth treatment; PHI, plant‐back interval.

[^10]: MRL: maximum residue level; GAP: Good Agricultural Practice; cGAP: critical GAP.

[^11]: Indicates that the MRL is proposed at the limit of quantification.

[^12]: NEU: Outdoor trials conducted in northern Europe, SEU: Outdoor trials conducted in southern Europe, Indoor: indoor EU trials or Country code: if non‐EU trials.

[^13]: Highest residue. The highest residue for risk assessment refers to the whole commodity and not to the edible portion.

[^14]: Supervised trials median residue. The median residue for risk assessment refers to the whole commodity and not to the edible portion.

[^15]: Conversion factor to recalculate residues according to the residue definition for monitoring to the residue definition for risk assessment.

[^16]: Studies with residues in the RAC at or close to the LOQ were disregarded (unless concentration may occur).

[^17]: Conversion factor for risk assessment in the processed commodity; median of the individual conversion factors for each processing residues trial.

[^18]: MRL: maximum residue level; SEU: southern Europe; NEU: northern Europe.

[^19]: Indicates that the MRL is set at the limit of analytical quantification (LOQ).

[^20]: Commodity code number according to Annex I of Regulation (EC) No 396/2005.

[^21]: STMR: supervised trials median residue; HR: highest residue; Mo: monitoring; RA: risk assessment; NEU: northern Europe; MRL: maximum residue level.

[^22]: The median residues (STMR~Mo~) refer to emamectin free base. The contribution of the photodegradation metabolites was not considered in the chronic risk assessment as residue data were not available. For monitoring, individual residue values of emamectin B1a benzoate were recalculated to emamectin (free base) using a conversion factor (CF) of 0.97 (EFSA, [2009](#efs25710-bib-0001){ref-type="ref"}).

[^23]: The median residues (STMR~Mo~) refer to emamectin B1a benzoate.

[^24]: For risk assessment, individual residue values of emamectin B1a benzoate were recalculated to emamectin B1a using a molecular weight (MW) CF of 0.88. Since the MW CF for EMA B1b is 0.88 and for the photodegradation metabolites ranged from 0.95 to 1, the individual residues (all \< LOQ) of EMA B1b benzoate, 8,9‐Z‐MBA1a, AB1a, MFB1a, FaB1a were not adjusted to express them as emamectin equivalents prior to be summed up (EFSA, [2018](#efs25710-bib-0004){ref-type="ref"}).

[^25]: Mammalians: swine, bovine, sheep, goats, equine, other farmed animals.

[^26]: IUPAC: International Union of Pure and Applied Chemistry; SMILES: simplified molecular‐input line‐entry system; InChiKey: International Chemical Identifier Key.

[^27]: ACD/Name 2015 ACD/Labs 2015 Release (File version N20E41, Build 75170, 19 December 2014).

[^28]: ACD/ChemSketch 2015 ACD/Labs 2015 Release (File version C10H41, Build 75059, 17 December 2014).
